Mineralys Therapeutics Inc

Research Mineralys Therapeutics Inc (MLYS) on Bullrun: market cap USD 2.22B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMLYS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.22B
• Financial periodFY2025
• Net income-USD 154.65M
• Free cash flow-USD 142.43M

Valuation Snapshot

latest market cap is USD 2.22B.

About Mineralys Therapeutics Inc

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc.

Frequently asked questions

What is Mineralys Therapeutics Inc's market cap?

Mineralys Therapeutics Inc's market capitalization is USD 2.22B.

What does Mineralys Therapeutics Inc do?

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.